arrow_back Trending Legislation
Share share

New Education Program on Biosimilar Drugs for Patients and Doctors.

This law aims to boost knowledge among doctors, patients, and caregivers about biological drugs, especially biosimilars, which are often cheaper alternatives. The government will create a dedicated website and educational programs to explain what these products are and how they are approved. Increased understanding of biosimilars can lead to greater treatment access and potentially lower medication costs for citizens.
Key points
Establishment of an official government website providing educational materials on biological products for the public and healthcare providers.
Requirement to explain key terms (e.g., "biosimilar," "interchangeable") and the standards for drug approval, building confidence in cheaper options.
Development of continuing education programs for healthcare providers regarding the safe prescribing and clinical use of biosimilars.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Advancing Education on Biosimilars Act of 2021
Print number: HR 1873
Sponsor: Rep. Bucshon, Larry [R-IN-8]
Process start date: 2021-03-12
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about New Education Program on Biosimilar Drugs for Patients and Doctors.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 1873.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-12.

What are the main provisions?

Key points include:

  • Establishment of an official government website providing educational materials on biological products for the public and healthcare providers.
  • Requirement to explain key terms (e.g., "biosimilar," "interchangeable") and the standards for drug approval, building confidence in cheaper options.
  • Development of continuing education programs for healthcare providers regarding the safe prescribing and clinical use of biosimilars.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Bucshon, Larry [R-IN-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

Analysis and Potential Impact of HR 1873

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health